Reversible pre-capillary pulmonary hypertension due to dasatinib

Respiratory Care

Volumn 59, Issue 5, 2014, Pages

  Buchelli Ramirez, Herminia L ^a   Álvarez Álvarez, Celso M ^a   Rodríguez Reguero, José J ^a   García Clemente, Marta M ^a   Casan Clarà, Pere ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Chronic myeloid leukemia; Drug induced; Long term therapy; Pulmonary hypertension

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; BRONCHODILATING AGENT; CARBON MONOXIDE; DASATINIB; NILOTINIB; SILDENAFIL; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONE; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LUNG ALVEOLUS HYPOVENTILATION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG SCINTISCANNING; LUNG VASCULAR RESISTANCE; MALE; MIDDLE AGED; NEW YORK HEART ASSOCIATION CLASS; PLEURA EFFUSION; PULMONARY HYPERTENSION; REMISSION; SYSTOLIC BLOOD PRESSURE; T WAVE; THORAX PAIN; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; CHEMICALLY INDUCED; HYPERTENSION, PULMONARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

HUMANS; HYPERTENSION, PULMONARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PURINES; PYRIMIDINES; SULFONES; THIAZOLES;

EID: 84899750704     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02692     Document Type: Article

References (13)

1. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34(6):1219-1263.
2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S43-S54.
3. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116(2):377-386.
4. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011;38(1):218-220.
5. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 2012;36(1):e4-e6.
6. Adir Y, Humbert M. Pulmonary hypertension in patients with chronic myeloproliferative disorders. Eur Respir J 2010;35(6):1396-1406.
7. Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary hypertension? BMC Pulm Med 2011; 11:30.
8. Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125(17):2128-2137.
9. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006;69(5):1527-1533.
10. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinibresistant and-intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26(19):3204-3212.
11. Quintás-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R, Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25(25):3908-3914.
12. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009;33(6):861-864.
13. Zakrzewski D, Seferynska I, Warzocha K, Hryniewiecki T. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia. Int J Hematol 2012;96(1): 132-135.